Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
15.93
+0.13 (0.82%)
At close: Aug 1, 2025, 4:00 PM
15.92
-0.01 (-0.06%)
After-hours: Aug 1, 2025, 7:32 PM EDT
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 609 employees as of September 30, 2024. The number of employees increased by 84 or 16.00% compared to the previous year.
Employees
609
Change (1Y)
84
Growth (1Y)
16.00%
Revenue / Employee
$895,253
Profits / Employee
-$236,402
Market Cap
2.20B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | 232 | 98 | 73.13% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARWR News
- 1 day ago - Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi - Business Wire
- 5 days ago - Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire
- 8 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 10 days ago - Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics - Business Wire
- 10 days ago - How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals - Seeking Alpha
- 11 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results - Business Wire
- 25 days ago - Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran - Business Wire